Effect of prophylactic intraocular pressure‑lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case–control study.
Indian J Ophthalmol
;
2016 Oct; 64(10): 762-766
Article
in English
| IMSEAR
| ID: sea-181297
ABSTRACT
Purpose:
To observe the effect of prophylactic intraocular pressure (IOP)‑lowering medication (brinzolamide) on IOP after ranibizumab intravitreal injections (IVIs). Materials andMethods:
This prospective case–control study included 352 eyes from 352 patients (1 eye per patient) who were treated with ranibizumab intravitreal injection and divided randomly into two groups. Two hundred and three patients in control group only received the ranibizumab IVI, but 149 patients in case group received one drop of prophylactic intraocular brinzolamide preinjection. The IOP was measured by noncontact tonometer before injection, at 10, 30, 120 min and 1 day after injection in a sitting position.Results:
The mean IOP measured before injection, at 10, 30, 120 min and 1 day after injection individually were 15.79 ± 2.21 mmHg, 19.33 ± 4.86 mmHg, 16.64 ± 2.93 mmHg, 16.17 ± 3.13 mmHg, and 15.07 ± 2.55 mmHg in case group and were 15.82 ± 2.57 mmHg, 21.34 ± 5.88 mmHg, 18.17 ± 4.06 mmHg, 17.59 ± 4.42 mmHg, and15.48 ± 2.92 mmHg in control group. Comparing two groups, the mean increase on IOP was statistically significant at 10, 30, 120 min postinjection (P < 0.05).Conclusions:
IVI of ranibizumab causes a considerable short‑term transient rise on IOP in most patients. The effect of prophylactic IOP‑lowering medication on IOP after IVIs can be statistically significant from 10 min to 2 h after IVIs.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Observational study
Language:
English
Journal:
Indian J Ophthalmol
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS